The Motley Fool

Google’s Healthcare Entrance Makes Me Bullish On AstraZeneca plc

AstraZeneca (LSE: AZN) (NYSE: AZN.US) has received significant amounts of criticism in recent years from investors.

Indeed, its inability to tackle the ‘patent cliff’ made the market de-rate shares downwards, leaving AstraZeneca shareholders with little to shout about.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

Previous management, meanwhile, did little to allay fears that the company would see vastly reduced revenue and profitability, with there being apparently little or nothing they could do about it.

However, such views now seem to be moderating somewhat and the news that Google is set to enter the healthcare industry should, in my view, help to show that AstraZeneca has a great deal to offer.

Indeed, Google recently unveiled the venture, called Calico, with the aim of attacking some of the most difficult scientific problems in diseases related to ageing. Although Google was not specific in exactly how it would go about achieving this aim, its investment will be sufficient to build research and development capabilities in a number of areas.

This got me thinking about the position that AstraZeneca finds itself in and, in fact, the news made me want to buy more shares in the FTSE 100 company for three reasons.

Firstly, AstraZeneca is already in a strong position in terms of its research and development capabilities.

Certainly, the company has not been as successful as investors had hoped in developing new treatments to replace ones coming off patent in recent years. However, the capacity exists to develop a strong pipeline of products, something that only a relatively small number of pharmaceutical companies across the world could compete with.

Secondly, as has been the case this year, AstraZeneca has the financial muscle to make up for lost time in terms of its research and development progress. In other words, it is able to buy smaller pharmaceutical companies that have attractive product pipelines to compensate for its lack of potential new treatments.

Although growth through acquisition may not be as preferable as organic growth, AstraZeneca’s balance sheet contains only moderate debt and, as such, can be further leveraged to grow the top and bottom lines.

Thirdly, AstraZeneca remains a great income stock. It currently yields an impressive 5.5%, with dividends being covered 2.3 times, meaning that even if profits were to fall significantly the dividend should still be at least maintained.

So, the news that Google is set to enter the healthcare market has made me realise that the research capabilities, financial firepower and yield of AstraZeneca make the FTSE 100 member worth buying.

“This Stock Could Be Like Buying Amazon in 1997”

I'm sure you'll agree that's quite the statement from Motley Fool Co-Founder Tom Gardner.

But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.

What's more, we firmly believe there's still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.

And right now, we're giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool.

Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge!

Peter owns shares in AstraZeneca. The Motley Fool owns shares in Google.

Our 6 'Best Buys Now' Shares

The renowned analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply enter your email address below to discover how you can take advantage of this.

I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement.